logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yung-Yeh Su

national health research institutes
H指数:13
被引数:420

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Linda Bartalini; Margherita Rimini; Masafumi Ikeda; Oluseyi Abidoye; Jessica Lucchetti; Lorenzo Antonuzzo; Jin Won Kim; Arndt Vogel; Angela Lamarca; Federico Nichetti; Anna Saborowski; Tiziana Pressiani; Caterina Vivaldi; Ilario Giovanni Rapposelli; Jeroen Dekervel; Chiara Braconi; David James Pinato; Emiliano Tamburini; Chiara Carlotta Pircher; Stefano Tamberi; Florian Castet; Monica Verrico; Alessandro Parisi; Nuno Couto; Hong Jae Chon; Andrea Martirena; Matteo Landriscina; Fabian Finkelmeier; Ester Oneda; Antonio Avallone; Emanuela Dell’Aquila; Lukas Perkhofer; Il Hwan Kim; Vincenzo Formica; Cidalia Maria de Sousa Pinto; Ingrid Garajova; Beodeul Kang; Salvatore Corallo; Elisabetta Fenocchio; Giovanni Farinea; Alessandro Pastorino; Anna Diana; Changhoon Yoo; Marta Schirripa; Maria Grazia Rodriquenz; Mario Scartozzi; Lucrezia Zumstein; Michele Ghidini; Gerald W. Prager; Giuseppe Aprile; Gian Paolo Spinelli; Yung-Yeh Su; Stephen L. Chan; Emily Warmington; Alessia Lancianese; Tomoyuki Satake; Tanios Bekaii-Saab; Daniele Lavacchi; Laura Passeri; Michele Ferrara; Minsu Kang; Alessandra Anna Prete; Silvia Bozzarelli; Mara Persano; Andrea Pretta; Gianluca Masi; Rita Balsano; Monica Niger; Sara Lonardi; Francesca Salani; Silvia Camera; Lorenzo Fornaro; Andrea Casadei-Gardini; Lorenza Rimassa
Response to comment on “Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX”

对“在解释改良FOLFIRINOX最佳初始相对剂量强度时考虑5-氟尿嘧啶剂量强度的未测量影响”的评论回复

Journal of the Formosan Medical Association
IF2.5
2026-05-220
OAAI
I-Wei Ho; Chung-Pin Li; Shih-Hung Yang; Hsiu-Tzu Wang; Ching-Yeh Lin; Yung-Yeh Su; Ching-Liang Ho; Wen-Chi Chou; Tai-Jan Chiu; Yu-Hsuan Shih; Yin-Hsun Feng; Yueh-Shih Chang; Chao-Chien Hung; Chang-Fang Chiu; Li-Yuan Bai
Response to Comment on “Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort”

对“改良FOLFIRINOX在胰管腺癌中的最佳初始相对剂量强度：一项回顾性多中心队列研究”的评论回复

Journal of the Formosan Medical Association
IF2.5
2026-05-050
OAAI
I-Wei Ho; Chung-Pin Li; Shih-Hung Yang; Hsiu-Tzu Wang; Ching-Yeh Lin; Yung-Yeh Su; Ching-Liang Ho; Wen-Chi Chou; Tai-Jan Chiu; Yu-Hsuan Shih; Yin-Hsun Feng; Yueh-Shih Chang; Chao-Chien Hung; Chang-Fang Chiu; Li-Yuan Bai
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study

将动脉内疗法加入免疫疗法可改善不可切除性肝细胞癌的预后：台湾多中心队列研究

Liver Cancer
IF9.1
2026-01-010
PRE
Lee, Teng-Yu; Lee, Pei-Chang; Shen, Ying-Chun; Hsu, Wei-Fan; Lai, Shiue-Wei; Chang, Ching-Wei; Su, Yung-Yeh; Su, Tung-Hung; Lin, Po-Ting; Dai, Chia-Yen; Hsu, Ching-Sheng; Chen, San-Chi; Rau, Kun-Ming; Lee, I-Cheng; Jhan, Song-Ru; Liu, Tsung-Hao; Lai, Hsueh-Chou; Wang, Tsang-En; Lin, Shi-Ming; Liang, Po-Cheng; Tseng, Cheng-Hao; Chang, Pi-Yi; Wu, Shu-Cheng; Wang, Hung-Wei; Lee, Shou-Wu; Huang, Yi-Hsiang
A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study

I/II期研究使用卡博替尼和兰瑞肽治疗分子靶向治疗或化疗失败的晚期GEP-NETs（SCALET）：TCOG T2221研究

ESMO Open
IF8.3
2026-01-010
OA
Hui‐Jen Tsai; Ming‐Huang Chen; Chin‐Fu Hsiao; L.-Y. Bai; Y.-Y. Chen; W.-C. Chou; Yung‐Yeh Su; M.-S. Dai; Y.-H. Liang; Y.-S. Shan; Chia‐Jui Yen; Tsung‐Hao Liu; J.-S. Chen; C.-Y. Yang; Chih‐Chieh Yen; J.-S. Chen; H.-C. Hsu; Yu‐Li Su; Chia‐Hsun Hsieh; Li‐Tzong Chen
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine–nab-paclitaxel failure: a propensity score-matched analysis

二线5-FU联合纳米脂质体伊立替康与FOLFOX/XELOX方案对比：在吉西他滨–白蛋白结合型紫杉醇治疗失败后的转移性胰腺癌中的倾向性评分匹配分析

ESMO Open
IF8.3
2025-11-070
OAAI
G. Trovato; D. Rossini; A. Guidolin; Y.-Y. Su; Y.-S. Shan; N.-J. Chiang; W.-C. Chou; L.-Y. Bai; C. Bagalà; M. Bensi; M. Niger; S. Marchesi; S.K. Garattini; A. Michelotti; A. Pretta; M. Scartozzi; C. Vivaldi; L. Bartalini; L. Procaccio; F. Bergamo; L. Antonuzzo; L.-T. Chen; L. Salvatore; G. Tortora
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration

Nivolumab联合ipilimumab治疗潜在可切除的肝细胞癌：长期疗效与生物标志物探索

Journal of Hepatology
IF33
2025-09-170
PREAI
Yih-Jyh Lin; Da-Liang Ou; Yung-Yeh Su; Chia-Lang Hsu; Chin-Fu Hsiao; Bor-Sheng Ko; San-Chi Chen; Hung-Wei Wang; Jing-Houng Wang; Yao-Ming Wu; Yung-Ming Jeng; Wei-Chen Lee; Shu-Cheng Chou; Teng-Wei Chen; Chang-Fang Chiu; null Shiuan Lin; Ching-Hung Hsieh; Chi-Chun Lee; Yen-Shen Shen; Ann-Lii Cheng; Li-Tzong Chen; Chiun Hsu
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan

胰腺癌同源重组基因的种系突变和临床结果: 台湾的多中心研究

JOURNAL OF BIOMEDICAL SCIENCE
IF12.1
2024-02-134
OAAI
Cheng, Siao Muk; Su, Yung-Yeh; Chiang, Nai-Jung; Wang, Chih-Jung; Chao, Ying-Jui; Huang, Chien-Jui; Tsai, Hui-Jen; Chen, Shang-Hung; Chang, Chi-Yen; Tsai, Chia-Rung; Li, Yi-Jie; Yen, Chia-Jui; Chuang, Shih-Chang; Chang, Jeffrey Shu-Ming; Shan, Yan-Shen; Hwang, Daw-Yang; Chen, Li-Tzong
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression

晚期肝细胞癌的免疫治疗后持久反应的结果-强调局部区域治疗的寡进展

LIVER CANCER
IF9.1
2024-02-010
OAAI
Liu, Tsung-Hao; Chen, San-Chi; Rau, Kun-Ming; Lu, Li-Chun; Lin, Po-Ting; Su, Yung-Yeh; Teng, Wei; Lai, Shiue-Wei; Yeh, Ren-Hua; Kao, Tsui-Mai; Lee, Pei-Chang; Wu, Chi-Jung; Chen, Chien-Hung; Hsu, Chih-Hung; Lin, Shi-Ming; Huang, Yi-Hsiang; Chen, Li-Tzong; Cheng, Ann-Lii; Shen, Ying-Chun

研究方向

暂未获取到该数据
L
Li‐Tzong Chen
H 指数:55论文数:538被引数:1.7万
Y
Yan‐Shen Shan
H 指数:41论文数:374被引数:7,520
N
Nai‐Jung Chiang
H 指数:22论文数:150被引数:1,498
C
Chiun Hsu
H 指数:56论文数:410被引数:1.8万
C
Chia‐Jui Yen
H 指数:36论文数:360被引数:1.2万
L
Li‐Yuan Bai
H 指数:26论文数:230被引数:4,149
C
Chien‐Jui Huang
H 指数:9论文数:48被引数:213
C
Chin‐Fu Hsiao
H 指数:46论文数:257被引数:6,778
C
Chung‐Pin Li
H 指数:42论文数:209被引数:8,026
S
San‐Chi Chen
H 指数:19论文数:127被引数:1,509